Advanced therapies for extraintestinal manifestations of IBD: a systematic review and meta-analysis.
Karan Sachdeva, Dhruv Manik, Tarun Chhibba et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy of advanced therapies (ATs) for extraintestinal manifestations (EIMs) in patients with inflammatory bowel diseases (IBD). The analysis included 49 studies, revealing that TNF antagonists and JAK inhibitors showed significant efficacy for musculoskeletal EIMs, with response rates of 61% and 65%, respectively, while vedolizumab had a lower efficacy of 42%.
Key findings
- TNF antagonists achieved a 61% response rate for musculoskeletal EIMs.
- JAK inhibitors demonstrated a 65% efficacy for musculoskeletal EIMs.
- For dermatologic EIMs, TNF antagonists and anti-ILs showed high efficacy rates of 89% and 91%, respectively.
- Vedolizumab had a significantly lower efficacy of 42% for musculoskeletal EIMs.
Why it matters
Understanding the effectiveness of advanced therapies for extraintestinal manifestations in IBD is crucial for optimizing treatment strategies. This knowledge can guide clinicians in selecting appropriate therapies for managing these complex conditions.